US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Renaissance Technologies Holdings

1,846.09

-66.6289-3.48%

Number of Gainers:33

Number of Losers:63

Number of Flat:- -

PE:- -

High:1,912.48

Open:1,912.48

Low:1,827.01

Close:1,912.72

Loading ...

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update

Morgan Stanley sees ‘limited impact’ to Lilly shares from Novo CagriSema data

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Hikma looks to launch generic versions of Novo Nordisk diabetes drugs, FT says

EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC

Is Micron Technology, Inc. (MU) the Most Undervalued US Stock to Buy According to Hedge Funds?

Unusually active option classes on open March 10th

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

BUZZ-Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study

F5 Insiders Sell US$2.9m Of Stock, Possibly Signalling Caution

Simply Wall St.

Snowflake Inc. (SNOW): Why Are Analysts Bullish On This Hot Growth Stock Right Now?

Franco-Nevada's Fourth-Quarter Results Top Views as Gold Prices Push Higher

1 Value Stock with Exciting Potential and 2 to Ignore

Here's What Monster Beverage's (NASDAQ:MNST) Strong Returns On Capital Mean

Simply Wall St.

The 2025 iHeartRadio Music Awards, Airing Monday, March 17 on FOX to Feature Performances by Bad Bunny, Billie Eilish, GloRilla, Gracie Abrams, Kenny Chesney, Muni Long, Nelly and More Live from Dolby Theatre in Los Angeles

CBAK Energy to Report fourth quarter & full year 2024 Unaudited Financial Results on Monday, March 17, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4532/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4532"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4532\",,,,,undefined,":{"symbol":"BK4532","market":"US","secType":"PLATE","nameCN":"Renaissance Technologies Holdings","latestPrice":1846.0924,"timestamp":1741636799999,"preClose":1912.7213,"halted":0,"volume":1253261147,"delay":0,"changeRate":-0.034835,"change":-66.628906,"pbRate":8.603584,"amount":150175594636.58835,"amplitude":0.044684,"prevYearClose":2026.1482,"fiveDayClose":1911.3298,"twentyDayClose":2013.1425,"turnoverRate":0.009742,"marketCap":20604169894688,"floatMarketCap":19268192223360,"peRate":31.475371},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4532\",,,,,undefined,":{"symbol":"BK4532","high":1912.4766,"amplitude":0.044684,"preClose":1912.7213,"low":1827.0077,"pbRate":"8.603584","latestPrice":1846.0924,"volume":1253261147,"delay":0,"open":1912.4766,"prevYearClose":2026.1482,"prevWeekClose":1912.7213,"prevMonthClose":1965.7411,"prevQuarterClose":2026.1482,"fiveDayClose":1911.3298,"twentyDayClose":2013.1425,"sixtyDayClose":2078.4277,"secType":"PLATE","market":"US","turnoverRate":0.009742,"peRate":31.475371,"marketCap":20604169894688,"floatMarketCap":19268192223360,"timestamp":1741636799999,"nameCN":"Renaissance Technologies Holdings"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4532\",,,,undefined,":{"bkCode":"BK4532","up":33,"down":63,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4532\",pageSize:16,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518222089","title":"Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222089","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518222089?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:48","pubTimestamp":1741614480,"startTime":"0","endTime":"0","summary":"Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug.The Danish company said CagriSema helped obese or overweight type 2 diabetics lose an average 15.7% of their weight in a late stage trial.Shares were down 8.1% in afternoon European trade.CagriSema is a two-drug combination that mixes its blockbuster Semaglutide drug found in Ozempic and Wegovy, with a experimental drug cagrilintide.An earlier study of the drug late last year disappointed investors with the weight-loss it achieved, wiping out nearly $100 billion of the drugmaker's stock-market value. That trial showed overweight or obese volunteers without type 2 diabetes lost an average of 22.7% of their weight, falling short of the 25% Novo Nordisk had expected.Sydbank senior analyst Soren Lontoft Hansen said the results of the trial appear to show CagriSema achieved greater weight-loss than Novo Nordisk's Wegovy did in a similar trial, but at the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"33fef3a9e838f3fdae4801e8afdfb9e5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756168.USD","BK4007","LU1093756325.SGD","BK4585","BK4599","NVO","BK4532"],"gpt_icon":1},{"id":"2518227942","title":"Morgan Stanley sees ‘limited impact’ to Lilly shares from Novo CagriSema data","url":"https://stock-news.laohu8.com/highlight/detail?id=2518227942","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518227942?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:45","pubTimestamp":1741614327,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight loss o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/morgan-stanley-sees-limited-impact-to-lilly-shares-from-novo-cagrisema-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/morgan-stanley-sees-limited-impact-to-lilly-shares-from-novo-cagrisema-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0158827781.USD","LU1720051017.SGD","LU2271345857.HKD","LU0098860793.USD","LU0225283273.USD","LU0314104364.USD","LU1093756168.USD","LU2347655156.SGD","LU1363072403.SGD","LU0106831901.USD","LU1989772840.SGD","LU0267386448.USD","BK4532","BK4581","BK4127","LU0158827948.USD","LU0006306889.USD","LU1162221912.USD","LU1732800096.USD","BK4007","BK4588","LU0971096721.USD","LU0106261372.USD","LU1720051108.HKD","LU0320765646.SGD","LU2023251221.USD","BK4516","LU1093756325.SGD","IE00BKVL7J92.USD","LU0795875086.SGD","BK4599","LU0154236417.USD","LU0795875169.SGD","LU2111349929.HKD","MS","LU2089283258.USD","LU1668664300.SGD","LU2028103732.USD","LU1732799900.SGD","BK4504","IE00BZ1G4Q59.USD","BK4534","BK4585","LU1548497426.USD","LU2089284900.SGD","LU2357305700.SGD","LU1989772923.USD","LU0912757837.SGD","NVO","LU2133065610.SGD"],"gpt_icon":0},{"id":"2518226812","title":"Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra","url":"https://stock-news.laohu8.com/highlight/detail?id=2518226812","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518226812?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:44","pubTimestamp":1741614240,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.The biopharmaceutical company said icotrokinra is a targeted oral peptide that selectively blocks the IL-23 receptor in adults with moderately to severely active ulcerative colitis.Protagonist said the study met its primary endpoint of clinical response in all icotrokinra dose groups evaluated. The study also demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remission, symptomatic remission and endoscopic improvement at week 12.Icotrokinra had a response rate of 63.5% for patients treated with the highest dose at week 12, versus 27% for placebo. Clinical remission and response rates continued to improve through week 28.Icotrokinra was well tolerated with the proportions of participants reporting one or more adverse events being similar between the icotroki","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","LU0912757837.SGD","LU1935042991.SGD","IE00B19Z3B42.SGD","BK4139","BK4581","LU0058720904.USD","LU1894683264.USD","IE00BDGV0183.EUR","LU1674673691.USD","LU1032466523.USD","LU0795875086.SGD","LU1732800096.USD","LU0320765646.SGD","BK4559","LU1221951129.SGD","LU1430594728.SGD","BK4532","LU1066051498.USD","LU1585245621.USD","SG9999002224.SGD","LU1221951046.USD","BK4585","LU2430703095.HKD","LU2592432038.USD","LU1718418525.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0234572021.USD","LU2347655156.SGD","LU0122379950.USD","IE00B3PB1722.GBP","LU0882574055.USD","PTGX","LU0289739699.SGD","IE00B42XCP33.USD","LU1244550494.USD","BK4592","LU0640476718.USD","LU0345769128.USD","LU2129689605.HKD","LU0889566641.SGD","LU1674673428.USD","LU2430703251.USD","IE00B1BXHZ80.USD","LU1914381329.SGD","IE00B7SZLL34.SGD","LU2129689431.USD","JNJ","LU0345770308.USD"],"gpt_icon":0},{"id":"2518622717","title":"Hikma looks to launch generic versions of Novo Nordisk diabetes drugs, FT says","url":"https://stock-news.laohu8.com/highlight/detail?id=2518622717","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518622717?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:41","pubTimestamp":1741614061,"startTime":"0","endTime":"0","summary":"Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents on ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hikma-looks-to-launch-generic-versions-of-novo-nordisk-diabetes-drugs-ft-says?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hikma-looks-to-launch-generic-versions-of-novo-nordisk-diabetes-drugs-ft-says?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","BK4532","BK4007","BK4599","FT","IE00BKVL7J92.USD","NVO","BK4588","BK4585","HKMPF","LU1093756168.USD"],"gpt_icon":0},{"id":"2518277677","title":"EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277677","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518277677?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:41","pubTimestamp":1741614060,"startTime":"0","endTime":"0","summary":"Bristol Myers BMY announced that the European Commission  has approved the blockbuster immuno-oncology drug Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma , a type of liver cancer.This approval is based on results of phase III CheckMate -9DW clinical study demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of Lenvima  or Nexavar .HCC accounts for 90% of liver cancer cases worldwide, which is the third most frequent cause of cancer death.In August 2024, the FDA also accepted BMY’s supplemental biologics license application  for Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable HCC and assigned a target action date of April 21, 2025.We note that the FDA granted accelerated approval in 2020 for the combination of Opdivo plus Yervoy as a second-line treatment fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ec-approves-bristol-myers-opdivo-134100082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B2B36J28.USD","LU0225771236.USD","MYE","LU2360032135.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","IE00B19Z3581.USD","LU0321505868.SGD","LU1323610961.USD","LU0109394709.USD","BMRN","LU0889565916.HKD","LU1868837300.USD","LU0882574055.USD","LU1868836914.USD","BK4559","GILD","LU0985481810.HKD","LU0321505439.SGD","LU2468319806.SGD","LU1868837136.USD","BK4568","IE0009355771.USD","LU1261432733.SGD","HCC","BMY","IE00BZ1G4Q59.USD","LU1032466523.USD","LU1093756325.SGD","LU1670710661.SGD","LU2242646821.SGD","BK4532","LU0306806265.USD","LU0237698245.USD","LU0289739699.SGD","EC","LU2089984988.USD","LU2125154778.USD","LU0061475181.USD","BK4007","LU1093756168.USD","BK4566","LU0306807586.USD","BK4139","IE00BJT1NW94.SGD","LU1670710588.SGD","BK4126","LU0320765992.SGD","BK4578","LU1074936037.SGD"],"gpt_icon":0},{"id":"2518622771","title":"Is Micron Technology, Inc. (MU) the Most Undervalued US Stock to Buy According to Hedge Funds?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518622771","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518622771?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:40","pubTimestamp":1741614055,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds.In this article, we are going to take a look at where Micron Technology, Inc.  stands against the other undervalued US stocks.Camporeale highlighted the difficulty of navigating the rapid pace of headlines surrounding trade discussions out of Washington. Entering the year with a 10% equity overweight, JP Morgan has since reduced this to 5%, reallocating some exposure to US, developed non-US, and emerging markets. Camporeale noted that while policy uncertainty raises questions about growth and earnings outlooks, the US economy remains strong, with a 4% unemployment rate, 3% GDP growth, and solid corporate balance sheets. He said that despite short-term market turbulence, recession risks remain low, and their portfolio maintains an equity overweight alongside high-yield exposure. He also pointed out that it is still early in President Trump's second term and too soon to draw definitive conclu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/micron-technology-inc-mu-most-134055481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4554","BK4579","BK4605","PSQ",".IXIC","LU2357305700.SGD","QID","NQmain","TQQQ","BK4543","BK4532","LU0158827781.USD","LU0889566641.SGD","LU2133065610.SGD","TSYW.SI","IE00B19Z3581.USD","QLD","BK4127","USAW.SI","IE00BZ1G4Q59.USD","BK4566","LU1162221912.USD","BK4512","LU0795875169.SGD","LU1720051108.HKD","LU2360106780.USD","LU0912757837.SGD","LU1548497426.USD","HBM","BK4168","LU0006306889.USD","LU0642271901.SGD","SQQQ","LU2111349929.HKD","LU0056508442.USD","LU1267930813.SGD","LU1316542783.SGD","LU0314104364.USD","LU2347655156.SGD","NVIW.SI","USJW.SI","LU0795875086.SGD","MU","BK4575","IE00B19Z3B42.SGD","LU0106261372.USD","LU2089283258.USD","LU0098860793.USD","MNQmain"],"gpt_icon":1},{"id":"2518247172","title":"Unusually active option classes on open March 10th","url":"https://stock-news.laohu8.com/highlight/detail?id=2518247172","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518247172?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:40","pubTimestamp":1741614015,"startTime":"0","endTime":"0","summary":"Unusual total active option classes on open include: Biogen (BIIB), Checkpoint Therapeutics (CKPT), Veren Inc. (VRN), Redfin (RDFN), Novo Nordisk (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-march-10th-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-march-10th-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4213","VRN","LU0154236417.USD","LU0889565916.HKD","LU0320765992.SGD","IE00BZ1G4Q59.USD","IE00B19Z9P08.USD","LU0109394709.USD","IE00B894F039.SGD","BK4548","RDFN","CKPT","BK4079","BK4599","IE00B19Z9Z06.USD","BK4588","IE00BKVL7J92.USD","BK4139","BK4533","BK4585","BIIB","LU0234570918.USD","NVO","LU1093756168.USD","LU1093756325.SGD","BK4532"],"gpt_icon":0},{"id":"2518271386","title":"Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271386","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518271386?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:40","pubTimestamp":1741614010,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Gilead Sciences  is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?Let's take a closer look at the stock's year-to-date performance to find out.Gilead Sciences is a member of our Medical group, which includes 1012 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Gilead Sciences is currently sporting a Zacks Rank of #2 .Gilead Sciences, Inc.  : Free Stock Analysi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-stock-outpacing-134010049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3T34201.USD","BK4585","LU2089984988.USD","LU1066051498.USD","LU1430594728.SGD","IE00B19Z3B42.SGD","ANIX","LU1585245621.USD","IE00B7SZLL34.SGD","LU0058720904.USD","LU0289739699.SGD","GILD","LU2468319806.SGD","LU0234570918.USD","LU0320765992.SGD","LU1571399168.USD","LU1839511570.USD","BK4583","LU2087621335.USD","BK4578","BK4588","BK4568","BK4139","IE00BKVL7J92.USD","LU0109394709.USD","BK4566","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","BK4532","IE0002270589.USD","BK4550","IE00B19Z3581.USD","LU0889565916.HKD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2518224920","title":"BUZZ-Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224920","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518224920?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:38","pubTimestamp":1741613898,"startTime":"0","endTime":"0","summary":"BUZZ-Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study ** Drug developer Protagonist Therapeutics' PTGX.O shares rise 30.4% to $50.02** PTGX says the mid-stage study of all three doses of once-daily experimental drug, icotrokinra, conducted by its collaboration partner Johnson & Johnson JNJ.N met its main goal in patients with ulcerative colitis** Ulcerative colitis, a form of inflammatory bowel disease , is a condition in which the lining of the large intestine  and rectum become inflamed** Co says the study showed significant improvements over placebo in clinical recovery, symptom relief, and showed reduction in signs of disease severity within 12 weeks** Co says the study achieved a response rate of 63.5% vs 27% for placebo** PTGX had risen 24.2% in the past 12 months, as of last close  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT0Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1732799900.SGD","LU1244550577.SGD","LU0466842654.USD","LU1894683348.USD","PTGX","JNJ","LU2505996681.GBP","BK4139","BK4585","IE0002141913.USD","IE00BJT1NW94.SGD","SG9999002224.SGD","IE00BDGV0183.EUR","LU1057294990.SGD","LU1430594728.SGD","LU1162221912.USD","IE00BVYPNV92.GBP","BK4592","LU0345769128.USD","IE0034235303.USD","LU0345770993.USD","IE00B3PB1722.GBP","LU1059921491.USD","LU1718418525.SGD","LU0882574055.USD","LU0345769631.USD","LU1221951129.SGD","LU0889566641.SGD","BK4534","BK4588","LU1506573853.SGD","LU2129689514.USD","BK4559","LU0058720904.USD","LU0912757837.SGD","LU0320765646.SGD","LU1280957306.USD","LU2602419157.SGD","LU0795875169.SGD","LU1674673428.USD","LU1023059063.AUD","LU2592432038.USD","IE00B19Z3B42.SGD","LU1066051811.HKD","LU1674673691.USD","SG9999001440.SGD","BK4504","LU1935042991.SGD","BK4532"],"gpt_icon":0},{"id":"2518186203","title":"F5 Insiders Sell US$2.9m Of Stock, Possibly Signalling Caution","url":"https://stock-news.laohu8.com/highlight/detail?id=2518186203","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518186203?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:36","pubTimestamp":1741613764,"startTime":"0","endTime":"0","summary":"In the last year, many F5, Inc. ( NASDAQ:FFIV ) insiders sold a substantial stake in the company which may have sparked...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8111000-choice1-main-header/1585186745276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8111000-choice1-main-header/1585186745276"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/tech/nasdaq-ffiv/f5/news/f5-insiders-sell-us29m-of-stock-possibly-signalling-caution","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FFIV","LU2506952170.USD","LU2506951958.HKD","LU2506952097.USD","LU0950375773.USD","BK4020","LU2506951875.HKD","BK4585","BK4532","LU0823417737.USD","LU0823417653.USD","BK4588"],"gpt_icon":0},{"id":"2518220889","title":"Snowflake Inc. (SNOW): Why Are Analysts Bullish On This Hot Growth Stock Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220889","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518220889?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:34","pubTimestamp":1741613695,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Hot Growth Stocks to Invest in According to Analysts.In this article, we are going to take a look at where Snowflake Inc.  stands against the other hot growth stocks.Morningstar, while highlighting the comment from Michael Arone , mentioned that non-US markets including China, the UK, and Germany have seen strong rallies. Notably, the market strategists continue to see a subtle transition in leadership. The broader markets have been struggling to find focus due to the uncertainties related to the future. The US Fed rate cuts are not guaranteed this year, while inflation remains sticky. Also, the potential impact of Trump’s economic policy proposals is unknown yet.UBS expects 2025 capex from the Big 4 US tech firms to increase by 35% to reach US$302 billion, with the firm seeing strong demand for frontier models. Due to the AI adoption trends fueling monetization, it projects mid-teens returns f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/snowflake-inc-snow-why-analysts-133455807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","LU1951198990.SGD","BK4548","LU1951200564.SGD","BK4613","BK4116","BK4505","BK4559","BK4551","LU0889565833.HKD","LU1923623000.USD","BK4554","BK4607","BK4585","BK4581","BK4532","BK4503","LU1803068979.SGD","LU0109392836.USD","SNOW","BK4588"],"gpt_icon":1},{"id":"2518274282","title":"Franco-Nevada's Fourth-Quarter Results Top Views as Gold Prices Push Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274282","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518274282?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:06","pubTimestamp":1741612018,"startTime":"0","endTime":"0","summary":"Franco-Nevada's  fourth-quarter results increased annually with earnings topping market estimates amid higher gold prices, while the company expects equivalent ounce sales of the precious metal to be higher this year.Franco-Nevada sold 120,063 gold equivalent ounces, or GEOs, in the fourth quarter, representing an annual decline of 21% largely due to the Cobre Panama halt, it said. \"We are encouraged that  has indicated a willingness to discuss Cobre Panama this year and that sentiment in Panama now appears more supportive of restarting the mine,\" according to Brink.Gold futures prices have surged about 30% over the past year, with Wells Fargo Investment Institute linking the rally to central bank purchases and investors seeking a haven amid geopolitical uncertainty, according to a note last week. Franco-Nevada's stock is up more than 20% in the same period and was 1.1% higher pre-bell Monday.For 2029, the group pegs the metric to come in at 490,000 to 550,000 ounces. Production resump","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/franco-nevada-apos-fourth-quarter-130658288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4017","LU2177674079.SGD","BK4588","BK4585","BK4532","FNV"],"gpt_icon":0},{"id":"2518682278","title":"1 Value Stock with Exciting Potential and 2 to Ignore","url":"https://stock-news.laohu8.com/highlight/detail?id=2518682278","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518682278?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:01","pubTimestamp":1741611660,"startTime":"0","endTime":"0","summary":"Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. Keeping that in mind, here is one value stock trading at a big discount to its intrinsic value and two with little support.Originally started as a joint venture between several media companies including The Washington Post and The New York Times, Cars.com  is a digital marketplace that connects new and used car buyers and sellers.Best-known for its HIV and Hepatitis treatments, Gilead Sciences  is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines.Scale is a double-e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/1-value-stock-exciting-potential-130100749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","BK4550","IE00B19Z3B42.SGD","BK4139","LU0234570918.USD","CARS","BK4583","BK4129","IE00B7SZLL34.SGD","BK4566","LU0289739699.SGD","IE00B3T34201.USD","LU1839511570.USD","BK4532","LU0058720904.USD","LU2089984988.USD","BK4588","LU1066051498.USD","IE00BSNM7G36.USD","LU0109394709.USD","GVA","BK4568","IE00BZ1G4Q59.USD","GILD","LU1066053197.SGD","IE00B19Z3581.USD","LU1430594728.SGD","LU1571399168.USD","BK4077","BK4585","LU0889565916.HKD","LU2087621335.USD","IE00BKVL7J92.USD","LU1585245621.USD","IE0002270589.USD","LU2468319806.SGD","BK4578"],"gpt_icon":0},{"id":"2518226392","title":"Here's What Monster Beverage's (NASDAQ:MNST) Strong Returns On Capital Mean","url":"https://stock-news.laohu8.com/highlight/detail?id=2518226392","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518226392?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:00","pubTimestamp":1741611617,"startTime":"0","endTime":"0","summary":"Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. That's why when we briefly looked at Monster Beverage's  ROCE trend, we were very happy with what we saw.If you haven't worked with ROCE before, it measures the 'return'  a company generates from capital employed in its business. The formula for this calculation on Monster Beverage is:. Return on Capital Employed = Earnings Before Interest and Tax  ÷ . So, Monster Beverage has an ROCE of 31%.  That's a fantastic return and not only that, it outpaces the average of 17% earned by companies in a similar industry.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-monster-beverages-nasdaq-mnst-130017719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","BK4504","PSQ","USAW.SI","BK4112","QID","NQmain","LU2095319765.USD","TSYW.SI","LU1035775433.USD","EBIT","SGXZ81514606.USD","BK4588",".IXIC","LU1069344957.HKD","LU0079474960.USD","LU0342679015.USD","LU2210149790.SGD","LU2326559502.SGD","TQQQ","BK4177","LU0345774631.USD","BK4532","IE00BKPKM429.USD","LU2210150020.SGD","NDAQ","BK4585","QLD","LU0345774391.USD","IE00BGHQF748.EUR","NVIW.SI","LU1435385759.SGD","SGXZ99366536.SGD","USJW.SI","SGXZ51526630.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4533","IE00B19Z9505.USD","MNST","LU1429558221.USD","SQQQ"],"gpt_icon":1},{"id":"2518222539","title":"The 2025 iHeartRadio Music Awards, Airing Monday, March 17 on FOX to Feature Performances by Bad Bunny, Billie Eilish, GloRilla, Gracie Abrams, Kenny Chesney, Muni Long, Nelly and More Live from Dolby Theatre in Los Angeles","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222539","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518222539?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:00","pubTimestamp":1741611600,"startTime":"0","endTime":"0","summary":"NEW YORK, March 10, 2025----iHeartMedia and FOX Entertainment today announced that the 2025 iHeartRadio Music Awards will feature performances by Bad Bunny, Billie Eilish, GloRilla, Gracie Abrams, Kenny Chesney, Muni Long, Nelly and more. Additionally, Rock & Roll Hall of Fame inductee, Kennedy Center Honoree, NAACP Image Award winner and two-time Grammy Award-winning Hip-Hop icon LL COOL J will return as host for the annual event airing LIVE from Dolby Theatre in Los Angeles, Monday, March 17  on FOX. The event also will broadcast live on iHeartRadio stations nationwide and on the iHeartRadio app.\"Excited to be back on the iHeartRadio stage to host this year’s awards. It’s going to be a night to remember—big energy, iconic moments and special collaborations you won’t want to miss,\" said LL COOL J.This year’s iHeartRadio Music Awards will also pay tribute to the resiliency and rebuilding of Los Angeles following the devastating wildfires affecting the entire community and will drive do","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/2025-iheartradio-music-awards-airing-130000521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","LU0868494617.USD","IE00BQXX3F31.USD","LU0256863902.USD","BK4566","BK4534","LU2362541513.USD","IE00B19Z8X17.USD","SGXZ23171101.USD","BK4108","IE00BKPKM429.USD","LU2552382132.HKD","LU0868494708.USD","LU0786609619.USD","LU1435385759.SGD","IE00B19Z8W00.USD","LU0082616367.USD","LU2357305700.SGD","LU2264538146.SGD","BK4588","SGXZ99366536.SGD","LU0882574139.USD","BK4125","BK4585","LU1548497426.USD","LU0006306889.USD","IE00BQXX3D17.EUR","LU1064131342.USD","LU1720051108.HKD","SG9999004303.SGD","LU2237957902.USD","LU2552382215.SGD","LU2362540622.SGD","LU1814569148.SGD","LU1429558221.USD","LU1988902786.USD","LU2108987350.USD","BK4527","BK4587","LU1989764664.SGD","LU0417517546.SGD","IE00BQXX3C00.GBP","BK4507","FOX","LU0719512351.SGD","LU1069344957.HKD","IHRT","LU2552382058.USD","BK4532"],"gpt_icon":1},{"id":"2518221404","title":"CBAK Energy to Report fourth quarter & full year 2024 Unaudited Financial Results on Monday, March 17, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518221404","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518221404?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:00","pubTimestamp":1741611600,"startTime":"0","endTime":"0","summary":"DALIAN, China, March 10, 2025 /PRNewswire/ -- CBAK Energy Technology, Inc.  , a leading lithium-ion battery manufacturer and electric energy solution provider inChina, today announced that it will report its unaudited financial results for the fourth quarter and full year endedDecember 31, 2024 onMonday, March 17, 2025, before the U.S. market opens. The earnings results will be available on the Company's Investor Relations website, and will be filed with the Securities and Exchange Commission on a Form 8-K.CBAK Energy's management will host an earnings conference call at8:00 AMU.S. Eastern Time onMonday, March 17, 2025.Safe Harbor StatementThis press release contains \"forward-looking statements\" that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cbak-energy-report-fourth-quarter-130000125.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cbak-energy-report-fourth-quarter-130000125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765489.SGD","LU1074936037.SGD","IE00BFSS8Q28.SGD","LU0061475181.USD","LU0211331839.USD","LU1162221912.USD","IE00B19Z3B42.SGD","CBAT","IE0004445015.USD","LU1585245621.USD","IE00BJJMRX11.SGD","IE00B7KXQ091.USD","BK4588","BK4131","LU0070302665.USD","IE00B19Z3581.USD","BK4550","UPS","LU0320765646.SGD","BK4532","BK4559","LU2133065610.SGD","LU0208291251.USD","BK4534","IE0002270589.USD","BK4585","LU0149725797.USD","IE00B7SZLL34.SGD","IE00BFSS7M15.SGD","LU2237438978.USD","BK4096","IE00BJJMRY28.SGD","LU1430594728.SGD"],"gpt_icon":0}],"pageSize":16,"totalPage":126,"pageCount":5,"totalSize":2005}]}}